Navigation Links
Questcor Pharmaceuticals to Present at Bank of America Merrill Lynch 2013 Healthcare Conference
Date:5/8/2013

ANAHEIM, Calif., May 8, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Bank of America Merrill Lynch 2013 Healthcare Conference in Las Vegas on May 14, 2013 at 4:20 PM PT/7:20 PM ET.

A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be available for approximately 90 days after the event.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor also provides specialty contract manufacturing services to the global pharmaceutical industry through its wholly-owned subsidiary BioVectra Inc. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.  


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
2. Questcor Pharmaceuticals Expands Repurchase Program
3. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Adamis Pharmaceuticals CEO Provides Update for Shareholders
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
8. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
9. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
10. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
11. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... ... 16, 2017 , ... Zansors has secured a patent ... or EKG) acquisition and monitoring device. This Zansors’ next-generation intellectual property (IP), will ... the skin, making them significantly easier to deploy and use. , Currently, ECG ...
(Date:5/15/2017)... ... May 15, 2017 , ... Tunnell Consulting announced that ... “The Key Role of Specifications in Process Validation,” at the Process Validation Summit ... will bring together leaders from the pharmaceutical and biotech industries to explore processes, strategies ...
(Date:5/12/2017)... , May 12, 2017 GreenMark Biomedical Inc. ... at the 36th annual Michigan Growth Capital Symposium (MGCS) ... Delaware corporation with facilities in ... investors in attendance, including more than 100 top venture ... to society through biobased targeting technologies. GreenMark ...
(Date:5/11/2017)... ... ... The key to unlocking the cause of Multiple Sclerosis may lie in ... that can rob people of their ability to see, speak, and walk. It is ... a genetic tendency towards the disease combined with an unidentified environmental trigger. The genetics ...
Breaking Biology Technology:
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
(Date:3/22/2017)... March 21, 2017 Vigilant Solutions , ... law enforcement agencies, announced today the appointment of retired ... of public safety business development. Mr. Sheridan ... experience, including a focus on the aviation transportation sector, ... recent position, Mr. Sheridan served as the Aviation Liaison ...
(Date:3/20/2017)... Pa. , March 20, 2017 PMD ... 2.0 personal spirometer and Wellness Management System (WMS), a ... Founded in 2010, PMD Healthcare is a Medical ... with a mission dedicated to creating innovative solutions that ... life. With that intent focus, PMD developed the first ...
Breaking Biology News(10 mins):